Crispr Therapeutics (NASDAQ:CRSP) Given Buy Rating at Piper Sandler
Piper Sandler reiterated their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a research note released on Thursday, TipRanks reports. They currently have a $104.00 target price on the stock.
CRSP has been the subject of a number of other research reports. Chardan Capital reiterated a buy rating and issued a $72.50 price target on shares of Crispr Therapeutics in a report on Thursday. Roth Capital boosted their price target on Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. ValuEngine lowered Crispr Therapeutics from a hold rating to a sell rating in a report on Friday, January 3rd. Oppenheimer boosted their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the company an outperform rating in a report on Monday, November 25th. Finally, William Blair reiterated a buy rating on shares of Crispr Therapeutics in a report on Thursday. Three analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have assigned a buy rating to the company’s stock. Crispr Therapeutics presently has a consensus rating of Buy and an average price target of $78.29.
Shares of NASDAQ CRSP traded down $2.32 during trading hours on Thursday, reaching $55.80. The stock had a trading volume of 1,623,146 shares, compared to its average volume of 1,113,728. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm has a market cap of $3.15 billion, a price-to-earnings ratio of -121.30 and a beta of 3.25. The business’s fifty day moving average price is $57.85 and its two-hundred day moving average price is $53.01. Crispr Therapeutics has a 52-week low of $30.75 and a 52-week high of $74.00.
In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares in the company, valued at $2,353,260. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $62.00, for a total value of $465,000.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $465,000. The disclosure for this sale can be found here. 21.40% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of CRSP. Nikko Asset Management Americas Inc. lifted its holdings in Crispr Therapeutics by 48.4% during the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after buying an additional 906,006 shares during the period. Orbimed Advisors LLC purchased a new stake in Crispr Therapeutics during the third quarter worth $21,167,000. FMR LLC lifted its holdings in shares of Crispr Therapeutics by 71.8% during the 4th quarter. FMR LLC now owns 952,369 shares of the company’s stock valued at $58,004,000 after purchasing an additional 398,012 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Crispr Therapeutics by 904.0% during the 4th quarter. Renaissance Technologies LLC now owns 394,564 shares of the company’s stock valued at $24,031,000 after purchasing an additional 355,264 shares during the last quarter. Finally, ARK Investment Management LLC lifted its holdings in shares of Crispr Therapeutics by 6.3% during the 4th quarter. ARK Investment Management LLC now owns 2,956,635 shares of the company’s stock valued at $180,074,000 after purchasing an additional 174,495 shares during the last quarter. Institutional investors own 50.01% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: What are municipal bonds?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.